abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Provides Vitargus® Update
02. August 2022 08:30 ET | ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
abvc-logo-nasdaq-440x386 (1).png
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
18. Juli 2022 08:30 ET | ABVC BioPharma, Inc.
-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
13. Juli 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
Zacks Places Share Value of ABVC BioPharma at $9.50
06. Juli 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Provides Vitargus® Update
30. Juni 2022 08:30 ET | ABVC BioPharma, Inc.
Vitargus® Receives Phase II Thailand Central Research Ethics Committee Approval  FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
21. Juni 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
16. Juni 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Termination of Two Contracts
10. Juni 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
01. Juni 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
abvc-logo-nasdaq-440x386 (1).png
ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners
25. Mai 2022 08:30 ET | ABVC BioPharma, Inc.
FREMONT, CA, May 25, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...